SavedAdd your journal

Journals / Archives of Rheumatology / 2021 / Cilt: 36 - Sayı: 3

The reliability and validity of the European League AgainstRheumatism Sjögren Syndrome Patient Reported Index in patientswith primary Sjögren syndrome: A Turkish version study

Elif GÜR KABUL
Pervin DEMİR
Bilge BAŞAKCI ÇALIK
Veli ÇOBANKARA
Aylin KESKİN
Pages
317–325
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The Turkish version of the ESSPRI was found to be clinically valid and reliable to be used in clinical evaluations and rehabilitationinterventions in patients with pSS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to assess the reliability and validity of the Turkish version of the European League Against Rheumatism (EULAR) SjögrenSyndrome Patient Reported Index (ESSPRI) (TR) in patients with primary Sjögren syndrome (pSS).
📊
Key Findings & Data:Materials and methods: A cross-sectional survey study design and analysis were used to assess the reliability and validity of the ESSPRI (TR)between March 2019 and July 2019.
💡
Conclusion & Impact:Conclusion: The Turkish version of the ESSPRI was found to be clinically valid and reliable to be used in clinical evaluations and rehabilitationinterventions in patients with pSS.
🔬Design:Survey & Empirical Study
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to assess the reliability and validity of the Turkish version of the European League Against Rheumatism (EULAR) SjögrenSyndrome Patient Reported Index (ESSPRI) (TR) in patients with primary Sjögren syndrome (pSS). Materials and methods: A cross-sectional survey study design and analysis were used to assess the reliability and validity of the ESSPRI (TR)between March 2019 and July 2019. A total of 30 patients (5 males, 25 females; mean age 54.1±10.5 years; range, 18 to 75 years) diagnosed as pSSaccording to revised American College of Rheumatology (ACR)/EULAR classification criteria were included. ESSPRI (TR) was applied to the patientswith face-to-face interviews twice: on their first visit and after an interval of 15 days. The test-retest reliability was assessed with the intraclasscorrelation coefficient (ICC), and the internal consistency of the multi-item subscales by calculating Cronbach alpha values. The correlations betweenbasal and stimulated salivary flow (BSF and SSF), Oral Health Impact Profile-14 (OHIP-14) and Oral Health-Related Quality of Life-UK (OHRQOL-UK)questionnaires were evaluated to determine the construct validity. Results: The ICC value for the test/retest reliability of ESSPRI (TR) was 0.925. The internal consistency was 0.682. There were low to moderatecorrelations between the ESSPRI (TR) total score and BSF (-0.39), SSF (-0.50), OHIP-14 total (0.57) and OHRQOL-UK total (-0.67). Conclusion: The Turkish version of the ESSPRI was found to be clinically valid and reliable to be used in clinical evaluations and rehabilitationinterventions in patients with pSS.

🔖

Cite This Article

KABUL, E. G., DEMİR, P., ÇALIK, B. B., ÇOBANKARA, V., KESKİN, A. (2022). The reliability and validity of the European League AgainstRheumatism Sjögren Syndrome Patient Reported Index in patientswith primary Sjögren syndrome: A Turkish version study. Archives of Rheumatology, Cilt: 36 - Sayı: 3, 317–325. https://ajindex.com/articles/447989

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ 2012;344:e3821
  2. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54
  3. Porola P, Laine M, Virkki L, Poduval P, Konttinen YT. The influence of sex steroids on Sjögren's syndrome. Ann N Y Acad Sci 2007;1108:426-32
  4. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 2010;9:A305-10
  5. Bloch KJ, Buchanan WW, Wohl MJ, Bunim JJ. Sjoegren’s syndrome. A clinical, pathological, and serological study of sixty-two cases. Medicine (Baltimore) 1965;44:187-231
  6. Kabasakal Y, Kitapcioglu G, Turk T, Oder G, Durusoy R, Mete N, et al. The prevalence of Sjögren's syndrome in adult women. Scand J Rheumatol 2006;35:379-83
  7. Kvarnström M, Ottosson V, Nordmark B, WahrenHerlenius M. Incident cases of primary Sjögren's syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol 2015;44:135-42
  8. Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjögren syndrome. Nat Rev Dis Primers 2016;2:16047
  9. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, et al. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial. Arthritis Care Res (Hoboken) 2017;69:528-35
  10. Ramos-Casals M, Font J. Primary Sjögren’s syndrome. In: Imboden J, Hellmann D, Stone J, editors. Current diagnosis and treatment in rheumatology. Upper Saddle River, NJ: McGraw-Hill; 2007. p. 237-45
  11. Stewart CM, Berg KM, Cha S, Reeves WH. Salivary dysfunction and quality of life in Sjögren syndrome: a critical oral-systemic connection. J Am Dent Assoc 2008;139:291-9
  12. Zelles T, Purushotham KR, Macauley SP, Oxford GE, Humphreys-Beher MG. Saliva and growth factors: the fountain of youth resides in us all. J Dent Res 1995;74:1826-32
  13. Bowman SJ, Pillemer S, Jonsson R, Asmussen K, Vitali C, Manthorpe R, et al. Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. Rheumatology (Oxford) 2001;40:1180-8
  14. Bowman SJ, Booth DA, Platts RG; UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheum